Huerta Milagros G, Nadler Jerry L
Division of Endocrinology and Metabolism, University of Virginia, P.O. Box 801405, Fontaine Research Park, 450 Ray C. Hunt Drive, Fontaine Medical Research Building, 1st Floor Room #1220, Charlottesville, VA 22908-1405, USA.
Curr Diab Rep. 2002 Oct;2(5):396-402. doi: 10.1007/s11892-002-0103-5.
Experimental and epidemiologic studies support the role of inflammation in the development of type 2 diabetes and atherosclerosis. Serum levels of inflammatory markers, in particular highly sensitive C-reactive protein, have been found to be strong predictors of increased risk for type 2 diabetes and cardiovascular disease independent of traditional risk factors. A beneficial effect of thiazolidinediones, angiotensin-converting enzyme inhibitors, and statins in the prevention of type 2 diabetes and cardiovascular events has recently been reported, and potential anti-inflammatory mechanisms of action for these compounds have been described. Prospective, randomized clinical trials are currently underway to confirm these initial findings and define indications for treatment of patients at risk.
实验和流行病学研究支持炎症在2型糖尿病和动脉粥样硬化发展过程中的作用。已发现炎症标志物的血清水平，尤其是高敏C反应蛋白，是独立于传统危险因素之外的2型糖尿病和心血管疾病风险增加的有力预测指标。最近有报道称噻唑烷二酮类药物、血管紧张素转换酶抑制剂和他汀类药物在预防2型糖尿病和心血管事件方面具有有益作用，并描述了这些化合物潜在的抗炎作用机制。目前正在进行前瞻性、随机临床试验以证实这些初步发现并确定对有风险患者的治疗指征。
